Mercer Global Advisors Inc. ADV Has $3.27 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Posted by on May 15th, 2023

Mercer Global Advisors Inc. ADV reduced its position in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 8.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 43,881 shares of the medical research company’s stock after selling 3,837 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Edwards Lifesciences were worth $3,274,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Advisors Asset Management Inc. raised its holdings in Edwards Lifesciences by 0.3% in the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after acquiring an additional 117 shares during the period. Geller Advisors LLC raised its holdings in Edwards Lifesciences by 6.5% in the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after acquiring an additional 120 shares during the period. Sycomore Asset Management raised its holdings in Edwards Lifesciences by 17.4% in the 4th quarter. Sycomore Asset Management now owns 944 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 140 shares during the period. Financial Architects Inc raised its holdings in Edwards Lifesciences by 5.1% in the 4th quarter. Financial Architects Inc now owns 2,893 shares of the medical research company’s stock valued at $216,000 after acquiring an additional 141 shares during the period. Finally, KCM Investment Advisors LLC raised its holdings in Edwards Lifesciences by 2.7% in the 1st quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock valued at $635,000 after acquiring an additional 142 shares during the period. 80.35% of the stock is owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, CEO Michael A. Mussallem sold 19,875 shares of Edwards Lifesciences stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $77.00, for a total transaction of $1,530,375.00. Following the completion of the transaction, the chief executive officer now owns 157,353 shares of the company’s stock, valued at $12,116,181. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Michael A. Mussallem sold 19,875 shares of Edwards Lifesciences stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $77.00, for a total transaction of $1,530,375.00. Following the completion of the transaction, the chief executive officer now owns 157,353 shares of the company’s stock, valued at $12,116,181. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 80,700 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $88.54, for a total transaction of $7,145,178.00. Following the transaction, the chief financial officer now directly owns 18,294 shares of the company’s stock, valued at approximately $1,619,750.76. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 216,216 shares of company stock worth $18,268,759. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $89.18 on Monday. Edwards Lifesciences Co. has a fifty-two week low of $67.13 and a fifty-two week high of $107.92. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.01 and a quick ratio of 2.17. The firm has a market capitalization of $54.25 billion, a P/E ratio of 37.00, a P/E/G ratio of 5.04 and a beta of 1.02. The company’s 50 day moving average price is $83.52 and its two-hundred day moving average price is $78.63.

Edwards Lifesciences (NYSE:EW – Get Rating) last issued its earnings results on Wednesday, April 26th. The medical research company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.39 billion. Edwards Lifesciences had a net margin of 27.07% and a return on equity of 25.81%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the business posted $0.60 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of several research analyst reports. Mizuho increased their price target on shares of Edwards Lifesciences from $85.00 to $95.00 in a report on Tuesday, April 25th. Sanford C. Bernstein cut shares of Edwards Lifesciences from an “outperform” rating to an “underperform” rating and lowered their target price for the stock from $95.00 to $66.00 in a report on Tuesday, January 31st. TheStreet raised shares of Edwards Lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, April 19th. Piper Sandler raised their target price on shares of Edwards Lifesciences from $80.00 to $83.00 in a report on Thursday, April 27th. Finally, Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $75.00 to $87.00 in a report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $89.42.

Edwards Lifesciences Profile

(Get Rating)

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Get Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.